# PKD/PKCm(Phospho-Ser910) Antibody

Catalog No: #11096

Package Size: #11096-1 50ul #11096-2 100ul #11096-4 25ul



Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com

### Description

Product Name	PKD/PKCm(Phospho-Ser910) Antibody				
Host Species	Rabbit				
Clonality	Polyclonal				
Purification	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates.				
	Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho				
	specific antibodies were removed by chromatogramphy using non-phosphopeptide.				
Applications	WB IF				
Species Reactivity	Ни				
Specificity	The antibody detects endogenous level of PKD/PKCm only when phosphorylated at serine 910.				
Immunogen Type	Peptide-KLH				
Immunogen Description	Peptide sequence around phosphorylation site of serine 910 (R-V-S(p)-I-L) derived from Human PKD/PKCm.				
Target Name	PKD/PKCm				
Modification	Phospho-Ser910				
Other Names	KPCD1; PKC-mu; PKCM; PKD; PRKCM				
Accession No.	Swiss-Prot: Q15139NCBI Protein: NP_002733.2				
Concentration	1.0mg/ml				
Formulation	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02%				
	sodium azide and 50% glycerol.				
Storage	Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.				


#### **Application Details**

Predicted MW: 115kd Western blotting: 1:500~1:1000 Immunofluorescence: 1:100~1:200

#### Images

	1	293	Ĩ	HUVEC	I	
КD	1	200	1	HOVEO	1	
170 —						
130 —	22					
95 —				100		PKD/PKCµ (pSer910)
72 —						
55 —						
43 —						
EGF	-		3	-	-	,
PMA	5			+	-	

Western blot analysis of extracts from EGF-treated 293 and PMA-treated HUVEC cells using PKD/PKCm(Phospho-Ser910) Antibody #11096.



Immunofluorescence staining of methanol-fixed Hela cells using PKD/PKCm(Phospho-Ser910) Antibody #11096.

## Background

Converts transient diacylglycerol. (DAG) signals into prolonged physiological effects, downstream of PKC. Involved in resistance to oxidative stress through activation of NF-kappa-B.

Matthews SA, et al. J Biol Chem 1999 Sep; 274(37): 26543-26549

Brandlin I, et al. J Biol Chem 2002 Feb; 277(8): 6490-6496

Storz P, et al. Mol Pharmacol 2004 Oct; 66(4): 870-879

Note: This product is for in vitro research use only and is not intended for use in humans or animals.